The White Bear Lake, Minn-based company reported six-month follow-up data for all 56 pivotal trial participants and submitted a second module of its modular PMA application to the FDA following the close of the quarter. Envoy Medical reported its third quarter 2026 financial results on Nov 5, 2026, while highlighting continued clinical and regulatory progress in its pivotal trial of the investigational Acclaim...
Continue reading at Hearing Review
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is a regulatory pipeline and financial update; the Acclaim implant is not yet FDA-approved for clinical use.
Progress toward FDA approval of the fully implanted Acclaim cochlear implant could expand treatment options for patients who prefer a device with no external components.
- 01All 56 pivotal trial participants reached the six-month follow-up milestone.
- 02Envoy submitted a second module of its modular Pre-Market Approval (PMA) application to the FDA.
- 03The Acclaim is a fully implanted cochlear implant — no external processor worn by the patient.
- 04Report covers Q3 2026 financials alongside the clinical trial update.
- 05Device remains investigational; FDA approval has not been granted.
All 56 pivotal trial participants completed six-month follow-up.
press releasepartially supportedEnvoy Medical submitted a second module of its modular PMA to the FDA.
press releasesupported